In summary, in our model, CD133+ cells showed the ability to promote the release of the hemopoietic and renoprotective hormone EPO in vivo and abrogated EPO reduction occurring after AKI by stimulating the release of the EPO of both mice and human origin. The gene discussed is EPO; the disease is acute kidney injury.